SI 613

Drug Profile

SI 613

Alternative Names: Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; Non-steroidal anti-inflammatory drug/hyaluronic acid; NSAID/hyaluronic acid; SI-613

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Seikagaku Corporation
  • Class Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis

Most Recent Events

  • 03 Feb 2017 Phase-III clinical trials in Osteoarthritis in Japan (Intra-articular)
  • 16 Feb 2016 Phase-II development is ongoing in Japan
  • 11 Dec 2014 Seikagaku Corporation initiates a phase II trial in Osteoarthritis in Japan (UMIN000015858)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top